Skip to main content
D

DIMERIX LIMITED — Investor Relations & Filings

Ticker · DXB ISIN · AU000000DXB7 ASX Professional, scientific and technical activities
Filings indexed 1,124 across all filing types
Latest filing 2021-08-15 Regulatory Filings
Country AU Australia
Listing ASX DXB

About DIMERIX LIMITED

https://dimerix.com/

Dimerix Limited focuses on the development of therapeutic treatments for inflammatory diseases, with a primary emphasis on kidney and respiratory conditions. The company utilizes its proprietary Receptor-Heteromer Investigation Technology (DMX-Technology) to identify and validate G protein-coupled receptor (GPCR) targets. Its lead candidate, DMX-200, is a chemokine receptor (CCR2) antagonist currently in Phase 3 clinical trials for the treatment of Focal Segmental Glomerulosclerosis (FSGS). The company is also advancing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD) and exploring applications for diabetic kidney disease. The core strategy involves targeting multiple signaling pathways simultaneously to address unmet medical needs in chronic inflammatory and fibrotic diseases.

Recent filings

Filing Released Lang Actions
Preliminary Final Report 2 pages 275.3KB
Regulatory Filings
2021-08-15 English
Annual Report to Shareholders 69 pages 2.6MB
Regulatory Filings
2021-08-15 English
Appendix 4G and Corporate Governance Statement 26 pages 497.5KB
Regulatory Filings
2021-08-15 English
Investor Presentation 34 pages 4.5MB
Regulatory Filings
2021-08-15 English
Trading Halt 2 pages 373.6KB
Regulatory Filings
2021-08-11 English
DMX-200 COVID-19 Study Opens More Sites in Europe and UK 3 pages 308.2KB
Regulatory Filings
2021-08-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.